Revvity Health Sciences, Inc.

Revvity Health Sciences, Inc., doing business as PerkinElmer Inc., delivers laboratory instrumentation, scientific equipment maintenance, specialized diagnostic platforms, and consumable reagents to federal agencies as a large business prime contractor across 250 distinct customer agencies, competing predominantly on full-and-open, sole-source, and simplified acquisition procedures without set-aside categories. The company operates as a subsidiary of Revvity Inc., a for-profit manufacturer headquartered in Waltham, Massachusetts, with primary NAICS concentration in analytical laboratory instrument manufacturing and precision equipment repair and maintenance.

Over the past several years, Revvity Health Sciences has grown its federal footprint to 6,838 total awards—nearly all prime contracts (100%)—with annual award counts declining from 155 in 2022 to 25 in 2026, reflecting a shift toward fewer but larger-value task orders and consolidations within parent vehicle structures. Combined potential value across the award portfolio reaches $876 million, with $333 million obligated year-to-date (38% realization). The vendor operates almost exclusively as a prime contractor and rarely subcontracts to other firms; SCI data shows zero average sub-hours share across prime service contracts, indicating vertical integration of delivery teams rather than reliance on subcontractor networks.

Customer concentration centers on health and defense research. The National Institutes of Health Office of the Director leads by award count (402 awards, $2.8 million potential value), followed by CDC Pittsburgh (204 awards, $55.5 million), and CDC Office of Acquisition Services (305 awards, $29.6 million). The two rankings diverge notably: CDC Pittsburgh and CDC Office of Acquisition Services anchor the potential-value rankings with $55.5 million and $29.6 million respectively, while NIH OD's large count carries modest dollars. Department of the Army Medical Command (216 awards, $18.5 million) and EPA Office of Research and Development (85 awards, $8.3 million) round out the top five customers by dollars. Top 20% of customers account for approximately 20% of awards; the concentration is broad rather than highly pegged to single agencies.

Revvity holds two named parent contract vehicles: a $10 million single-award Blanket Purchase Agreement with the National Eye Institute (awarded March 29, 2024, expiring December 31, 2026), and a Naval Sea Systems Command Indefinite Delivery Contract valued at $86,484 for ICP-MS maintenance (September 23, 2022–September 2025). Task orders under these vehicles are limited: the NEI BPA has hosted two task orders ($18,465.92 and $10,347 to date), while NAVSEA issued three delivery orders ($29,964, $28,812, and $27,708) against its IDC. The vast majority of Revvity's federal work flows through a parent vehicle called "Scientific Equipment and Services," which has generated 1,042 task orders valued at $561.8 million combined potential value—the dominant vehicle in the portfolio.

Capability framing derives from concrete award work: Revvity supplies analytical laboratory instrumentation (Operetta CLS and Opera Phenix high-content imaging systems, IVIS imaging platforms, MicroBeta scintillation counters, Cellometer automated cell counters, Janus liquid-handling platforms, inductively coupled plasma mass spectrometers, and gamma counters); delivers preventative maintenance, emergency repair, and "Gold/Silver/Bronze" tiered service plans for these systems; provides consumable reagents and assay kits (HTRF assay kits, AlphaLISA kits, radioactive tracers, scintillation cocktails, DNA/RNA extraction kits); performs one-time on-site service and emergency repairs; and supplies specialized equipment such as gamma counter detectors, microscope objectives, and data acquisition computers. Representative prime work includes a $9.263 million cost-no-fee definitive contract with the Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) for the MARTY (Multiplex, Accurate, Rapid, Testing for You) diagnostic platform (awarded September 30, 2024, completing August 31, 2026); a $696,235.12 firm fixed-price purchase order from NCATS for preventative maintenance and repair on one Operetta CLS, six Opera Phenix systems, a Flex 750 plate handler, and a Robot Fixed Cell unit (awarded September 24, 2025, performance through September 23, 2026); and a $769,846.76 sole-source annual service and maintenance contract from NIAID for two Operetta CLS and six Opera Phenix systems (awarded September 24, 2026, completing September 23, 2027). At the lower end, Revvity supplies single instruments and consumables in the $8,000–$50,000 range across multiple NIH institutes, VA networks, CDC divisions, and DOD commands.

Activity trajectory shows declining award frequency despite sustained or growing dollar value, indicative of consolidation into larger standing orders and indefinite delivery structures. SCI-reportable service contract invoicing totaled $2.6 million across FY2022–FY2025 (FY2022: $2.1 million; FY2024: $463 thousand; FY2023 and FY2025 showing zero SCI invoicing), with minimal federal FTE delivery (0.3 FTEs in FY2022, 0.1 in FY2024). Government-paid hourly rates on SCI contracts ranged from a 10th percentile of $1,421.49/hr to a median of $1,733.96/hr to a 90th percentile of $3,385.59/hr, reflecting service labor for technicians and field engineers performing maintenance and repairs. Fifty-five awards worth $9.1 million combined potential value face ultimate completion within the next twenty-four months, presenting recompete exposure.

Revvity competes exclusively as a large business in full-and-open competition and sole-source procurements, carrying no SBA designations or set-aside participation. The company's OEM status as the original equipment manufacturer of proprietary imaging and analytical platforms anchors many sole-source justifications; contracting officers frequently cite Revvity's exclusive capability to provide certified parts, factory-trained technicians, and proprietary software updates as the basis for non-competitive awards. Subcontract exposure is minimal: only four sub-award records appear in the source, distributed across KBR Wyle Services, Medical Science & Computing, Verus Research, and Consolidated Nuclear Security, with no systemic subcontracting relationship.

Federal grant activity is light: one sub-grant from Executive Office of the Governor of Delaware (effective January 1, 2025) for hearing screening and early intervention services data collection indicates marginal position in grant funding relative to the contract-dominated portfolio.

Parent company Revvity Inc. houses the Medical Imaging, LLC division; a named subsidiary Euroimmun US Incorporated appears in corporate structure records but carries no distinct award activity in the source.